{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:01:51Z","timestamp":1762459311898},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T00:00:00Z","timestamp":1439510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T00:00:00Z","timestamp":1439510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/cgt.2015.36","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T10:21:20Z","timestamp":1439547680000},"page":"438-444","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy"],"prefix":"10.1038","volume":"22","author":[{"given":"I D","family":"Iankov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C B","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A B","family":"D'Assoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J N","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Domingo-Musibay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C M","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A A","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Aderca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Federspiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,14]]},"reference":[{"key":"BFcgt201536_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BFcgt201536_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","volume":"15","author":"J Bell","year":"2014","unstructured":"Bell J, McFadden G . Viruses for tumor therapy. Cell Host Microbe 2014; 15: 260\u2013265.","journal-title":"Cell Host Microbe"},{"key":"BFcgt201536_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10549-009-0602-z","volume":"122","author":"ID Iankov","year":"2010","unstructured":"Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat 2010; 122: 745\u2013754.","journal-title":"Breast Cancer Res Treat"},{"key":"BFcgt201536_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/mt.2012.4","volume":"20","author":"ID Iankov","year":"2012","unstructured":"Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN et al. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther 2012; 20: 1139\u20131147.","journal-title":"Mol Ther"},{"key":"BFcgt201536_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-006-9200-5","volume":"99","author":"CJ McDonald","year":"2006","unstructured":"McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 2006; 99: 177\u2013184.","journal-title":"Breast Cancer Res Treat"},{"key":"BFcgt201536_CR6","first-page":"1401","volume-title":"Fields Virology","author":"D Griffin","year":"2001","unstructured":"Griffin D . Measles virus. In: Knipe DM, Howley PM (eds). Fields Virology, 4th edn. Lippincott, Williams & Wilkins: Philadelphia, PA, USA, 2001, pp 1401\u20131441."},{"key":"BFcgt201536_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9","volume":"70","author":"L Bjorge","year":"1997","unstructured":"Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S . Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70: 14\u201325.","journal-title":"Int J Cancer"},{"key":"BFcgt201536_CR8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature10639","volume":"480","author":"MD Muhlebach","year":"2011","unstructured":"Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011; 480: 530\u2013533.","journal-title":"Nature"},{"key":"BFcgt201536_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/35022579","volume":"406","author":"H Tatsuo","year":"2000","unstructured":"Tatsuo H, Ono N, Tanaka K, Yanagi Y . SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000; 406: 893\u2013897.","journal-title":"Nature"},{"key":"BFcgt201536_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1172\/JCI27177","volume":"116","author":"A Amedei","year":"2006","unstructured":"Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006; 116: 1092\u20131101.","journal-title":"J Clin Invest"},{"key":"BFcgt201536_CR11","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1128\/iai.63.6.2213-2220.1995","volume":"63","author":"DJ Evans Jr","year":"1995","unstructured":"Evans DJ Jr, Evans DG, Takemura T, Nakano H, Lampert HC, Graham DY et al. Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun 1995; 63: 2213\u20132220.","journal-title":"Infect Immun"},{"key":"BFcgt201536_CR12","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.4049\/jimmunol.1400339","volume":"193","author":"M Ramachandran","year":"2014","unstructured":"Ramachandran M, Jin C, Yu D, Eriksson F, Essand M . Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration. J Immunol 2014; 193: 2287\u20132296.","journal-title":"J Immunol"},{"key":"BFcgt201536_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","volume":"70","author":"AS Nikonova","year":"2013","unstructured":"Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr, Golemis EA . Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 2013; 70: 661\u2013687.","journal-title":"Cell Mol Life Sci"},{"key":"BFcgt201536_CR14","doi-asserted-by":"publisher","first-page":"21849","DOI":"10.1074\/jbc.M110.141010","volume":"285","author":"RD Van Horn","year":"2010","unstructured":"Van Horn RD, Chu S, Fan L, Yin T, Du J, Beckmann R et al. Cdk1 activity is required for mitotic activation of aurora A during G2\/M transition of human cells. J Biol Chem 2010; 285: 21849\u201321857.","journal-title":"J Biol Chem"},{"key":"BFcgt201536_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/onc.2012.628","volume":"33","author":"AB D'Assoro","year":"2014","unstructured":"D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A et al. The mitotic kinase Aurora\u2014a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene 2014; 33: 599\u2013610.","journal-title":"Oncogene"},{"key":"BFcgt201536_CR16","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-07-5268","volume":"14","author":"Y Nadler","year":"2008","unstructured":"Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y . Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008; 14: 4455\u20134462.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201536_CR17","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1038\/sj.onc.1209707","volume":"25","author":"X Wang","year":"2006","unstructured":"Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006; 25: 7148\u20137158.","journal-title":"Oncogene"},{"key":"BFcgt201536_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.bbagrm.2010.09.004","volume":"1799","author":"H Katayama","year":"2010","unstructured":"Katayama H, Sen S . Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta 2010; 1799: 829\u2013839.","journal-title":"Biochim Biophys Acta"},{"key":"BFcgt201536_CR19","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1158\/1078-0432.CCR-12-0571","volume":"18","author":"A Cervantes","year":"2012","unstructured":"Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K et al. Phase I pharmacokinetic\/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 4764\u20134774.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201536_CR20","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1158\/1078-0432.CCR-12-0589","volume":"18","author":"EC Dees","year":"2012","unstructured":"Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K et al. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012; 18: 4775\u20134784.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201536_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","volume":"32","author":"JW Friedberg","year":"2014","unstructured":"Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014; 32: 44\u201350.","journal-title":"J Clin Oncol"},{"key":"BFcgt201536_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2012.06.040","volume":"127","author":"UA Matulonis","year":"2012","unstructured":"Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 2012; 127: 63\u201369.","journal-title":"Gynecol Oncol"},{"key":"BFcgt201536_CR23","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1128\/JVI.73.11.9568-9575.1999","volume":"73","author":"WP Duprex","year":"1999","unstructured":"Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK . Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999; 73: 9568\u20139575.","journal-title":"J Virol"},{"key":"BFcgt201536_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/mt.2009.92","volume":"17","author":"ID Iankov","year":"2009","unstructured":"Iankov ID, Hillestad ML, Dietz AB, Russell SJ, Galanis E . Converting tumor-specific markers into reporters of oncolytic virus infection. Mol Ther 2009; 17: 1395\u20131403.","journal-title":"Mol Ther"},{"key":"BFcgt201536_CR25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.vaccine.2010.12.020","volume":"29","author":"ID Iankov","year":"2011","unstructured":"Iankov ID, Haralambieva IH, Galanis E . Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine 2011; 29: 1710\u20131720.","journal-title":"Vaccine"},{"key":"BFcgt201536_CR26","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1128\/CVI.00008-08","volume":"15","author":"IH Haralambieva","year":"2008","unstructured":"Haralambieva IH, Ovsyannikova IG, Vierkant RA, Poland GA . Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity. Clin Vaccine Immunol 2008; 15: 1054\u20131059.","journal-title":"Clin Vaccine Immunol"},{"key":"BFcgt201536_CR27","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3892\/or.2013.2313","volume":"29","author":"AA Leontovich","year":"2013","unstructured":"Leontovich AA, Salisbury JL, Veroux M, Tallarita T, Billadeau D, McCubrey J et al. Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. Oncol Rep 2013; 29: 1785\u20131788.","journal-title":"Oncol Rep"},{"key":"BFcgt201536_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-9966-31-51","volume":"31","author":"W Zhu","year":"2012","unstructured":"Zhu W, Wei L, Zhang H, Chen J, Qin X . Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo. J Exp Clin Cancer Res 2012; 31: 51.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFcgt201536_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/rmv.455","volume":"15","author":"AK Fielding","year":"2005","unstructured":"Fielding AK . Measles as a potential oncolytic virus. Rev Med Virol 2005; 15: 135\u2013142.","journal-title":"Rev Med Virol"},{"key":"BFcgt201536_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s10637-014-0121-6","volume":"32","author":"G Falchook","year":"2014","unstructured":"Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X et al. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs 2014; 32: 1181\u20131187.","journal-title":"Invest New Drugs"},{"key":"BFcgt201536_CR31","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/1535-7163.MCT-10-0299","volume":"9","author":"T Macarulla","year":"2010","unstructured":"Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010; 9: 2844\u20132852.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201536_CR32","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-12-0436","volume":"18","author":"KJ Brewer Savannah","year":"2012","unstructured":"Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E et al. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res 2012; 18: 4633\u20134645.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201536_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-012-2171-9","volume":"135","author":"W Fiskus","year":"2012","unstructured":"Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S et al. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Treat 2012; 135: 433\u2013444.","journal-title":"Breast Cancer Res Treat"},{"key":"BFcgt201536_CR34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1158\/1535-7163.MCT-11-0623","volume":"11","author":"V Sehdev","year":"2012","unstructured":"Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J et al. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 2012; 11: 763\u2013774.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201536_CR35","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00280-013-2305-8","volume":"72","author":"S Palani","year":"2013","unstructured":"Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J et al. Preclinical pharmacokinetic\/pharmacodynamic\/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol 2013; 72: 1255\u20131264.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFcgt201536_CR36","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/mt.2010.189","volume":"18","author":"L Heinemann","year":"2010","unstructured":"Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R et al. The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther 2010; 18: 2085\u20132093.","journal-title":"Mol Ther"},{"key":"BFcgt201536_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1677\/ERC-10-0234","volume":"18","author":"S Libertini","year":"2011","unstructured":"Libertini S, Abagnale A, Passaro C, Botta G, Barbato S, Chieffi P et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer 2011; 18: 129\u2013141.","journal-title":"Endocr Relat Cancer"},{"key":"BFcgt201536_CR38","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.3892\/or.2013.2359","volume":"29","author":"WG Zeng","year":"2013","unstructured":"Zeng WG, Li JJ, Hu P, Lei L, Wang JN, Liu RB . An oncolytic herpes simplex virus vector, G47Delta, synergizes with paclitaxel in the treatment of breast cancer. Oncol Rep 2013; 29: 2355\u20132361.","journal-title":"Oncol Rep"},{"key":"BFcgt201536_CR39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3892\/ijmm.2013.1319","volume":"31","author":"NC Frewer","year":"2013","unstructured":"Frewer NC, Ye L, Sun PH, Owen S, Ji K, Frewer KA et al. Potential implication of IL-24 in lymphangiogenesis of human breast cancer. Int J Mol Med 2013; 31: 1097\u20131104.","journal-title":"Int J Mol Med"},{"key":"BFcgt201536_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00262-006-0175-1","volume":"56","author":"M Zheng","year":"2007","unstructured":"Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK et al. Human interleukin 24 (MDA-7\/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother 2007; 56: 205\u2013215.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcgt201536_CR41","first-page":"2726","volume":"133","author":"SK Bhutia","year":"2013","unstructured":"Bhutia SK, Das SK, Azab B, Menezes ME, Dent P, Wang XY et al. Targeting breast cancer-initiating\/stem cells with melanoma differentiation-associated gene-7\/interleukin-24. Int J Cancer 2013; 133: 2726\u20132736.","journal-title":"Int J Cancer"},{"key":"BFcgt201536_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","volume":"75","author":"E Galanis","year":"2015","unstructured":"Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 2015; 75: 22\u201330.","journal-title":"Cancer Res"},{"key":"BFcgt201536_CR43","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","volume":"89","author":"SJ Russell","year":"2014","unstructured":"Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89: 926\u2013933.","journal-title":"Mayo Clin Proc"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201536","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T12:31:38Z","timestamp":1647952298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,14]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFcgt201536"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2015.36","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,14]]},"assertion":[{"value":"11 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}